Repositioning across species
a therapeutic for one species becomes a candidate for another
Life is interconnected, and our platform treats it that way. Because our models are cross-species by design, every measurement we make improves predictions for humans and animals at once. A discovery in one species can point the way to a cure in another — human or animal alike.
Closely related orthologs fold almost identically, so structure-prediction models see no difference between them. Our sequence-based model does: it predicts how binding shifts from one species to another, recovering textbook divergence cases like AHR, CYP11B, and MAO. Spearman ρ ≈ 0.51, where structure-prediction baselines sit near zero.
Cross-species affinity-shift prediction. Higher is better. Method and sample footnoted at publication.
Novel Sites spans 1.34 million proteins across 78 complete proteomes — livestock, companion, primate, and biomedical model species. The same engine reads across all of them.
| Previous largest | Novel Sites | |
|---|---|---|
| Complete proteomes | 10 | 78 |
| Proteins | 101,813 | 1,344,869 |
| Detection methods | 5 | 6 |
Roughly 13× more proteins than the previous largest binding-site dataset (Bender DB). Open, and targeted for release October 2026.
Interested in early access? Get in touch →
The companion and farm animals that share our world often suffer for the way they were bred or used. A platform that helps people can help them too — and reading across species turns that into concrete work:
a therapeutic for one species becomes a candidate for another
cross-species prediction reduces animal testing by pointing to the right experiments first
naturally occurring cancers in companion animals, not purpose-bred models, de-risk human relevance
equine, camel, and livestock health that conventional pipelines ignore